PCSK9 and cardiovascular disorder: Monoclonal antibodies target to PCSK9 are relatively novel lipid-lowering agents that have benefits in reducing the risk of cardiovascular disease (Giugliano et al., 2017; Schwartz et al., 2018; Koskinas et al., 2019).